EN DE
Watch Cellectis SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cellectis SA (CLLS) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Cellectis SA stock $0.50, price $1.08, upside -53.7%, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in France

CS Cellectis SA logo Thin data Oct 28, 2026

Cellectis SA

CLLS · US
Very expensive, weak quality

Our calculation puts a fair price 54% below what the stock costs today.

Moderate debt
Revenue last quarter 62% below a year ago.
Fair value $0.5000 · Strongly overvalued (−53.7%)
Quality 33/100
Weak Growth (revenue 5y −0.3 %/yr in USD)
Loss-making · -102.3% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 10/100 · thin data
Thin data
Watch Cellectis SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.33 $0.9255 Fair Value $0.5000 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.

How to read this chart

60‑month range $0.9255 – $15.33 · fair‑value band $0.3700 – $0.7500 · the $1.08 price screens above the $0.5000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.

Follow Cellectis in your weekly email

Every Wednesday you see whether Cellectis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Show moreShow less

The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma.

Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Stock analysis

Cellectis SA (CLLS) currently trades at $1.08, while our model-based Fair Value estimate is $0.5000, 53.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.3700 (bear) to $0.7500 (bull), the price of $1.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Cellectis SA reported revenue of $72.9M in FY2025 versus $73.9M in FY2021, a compound −0.3%/yr. Reported net income was −$67.6M in FY2025.

Key figures

Market cap $109M Micro · P/S ratio 1.66 · EPS (TTM) $−0.6400 · Net margin −102% · Return on equity −94.5% · Return on assets (EBIT) −22.3% · Operating margin −341% · Revenue (TTM) $63.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −54%, CLLS screens richer than that median.

Fair Value models

Bear $0.3700 Fair Value $0.5000 Bull $0.7500
Price $1.08 · Upside -53.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.5200 $0.6900 $1.04 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.5200 $0.6900 $1.04 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 38
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 0
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+75.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Start year 2020 (pandemic). Over 10 years: +2.9% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−115.5% (2020) → −45.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CLLS screens overvalued: fair value 54% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cellectis SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 587 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −53.7% · Below median
Profitability
Return on assets −20.8% · Below median
Net margin (12 months) −102.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −62.1% · Bottom 25%
Balance sheet
Debt / equity 0.68× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.43× · Cheaper than median
P/S (12 months) 1.70× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)66 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $818.77 $1,275 +56% vs CLLS
Vertex Pharmaceuticals Incorporated VRTX $540.00 $594.00 +10% vs CLLS
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs CLLS
Genmab A/S GMAB kr 3,912 kr 4,303 +10% vs CLLS
WuXi Biologics (Cayman) Inc 2269 HK$45.06 HK$49.57 +10% vs CLLS
argenx SE ARGX $882.48 $908.40 +3% vs CLLS
CSL Limited CSL A$200.73 A$178.58 −11% vs CLLS
BeOne Medicines AG 6160 HK$217.60 HK$153.56 −29% vs CLLS
Celltrion, Inc 068270 189,300 KRW 74,945 KRW −60% vs CLLS
Royalty Pharma plc RPRX $64.76 $19.01 −71% vs CLLS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cellectis SA · Fair Value
$0.5000 −54%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cellectis SA Fair Value". https://www.fairvalue-calculator.com/stock/CLLS

Frequently asked questions

Is Cellectis SA (CLLS) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of $0.5000 versus a price of $1.08, about −54% upside (overvalued).
What is the fair value of CLLS?
Our model-based fair value for Cellectis SA is $0.5000 (as of Oct 28, 2026), built from audited fundamentals. The current price: $1.08.
What is the quality score of CLLS?
Cellectis SA has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cellectis SA (CLLS)?
Our model-based price target is the fair value of $0.5000 (as of Oct 28, 2026) from 1 valuation models. Cautious scenario $0.3700, optimistic scenario $0.7500. It is a calculation from audited fundamentals, not an analyst target.
What is the Cellectis SA stock forecast for 2026?
Our models put fair value at $0.5000, about −54% upside versus a price of $1.08 (overvalued). Cautious scenario $0.3700, optimistic scenario $0.7500. The calculation is refreshed regularly with new filings.
What is the revenue of Cellectis SA (CLLS)?
Cellectis SA reported trailing-twelve-month revenue of about $63.8M (latest available figure, as of Oct 28, 2026).
What is the intrinsic value of Cellectis SA (CLLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cellectis SA it is $0.5000 per share (as of Oct 28, 2026), against a price of $1.08. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cellectis SA stock overvalued or undervalued in 2026?
As of Oct 28, 2026, CLLS trades above its calculated fair value: price $1.08, fair value $0.5000, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLLS?
No. The price is what the market pays today ($1.08); the fair value is what the company's own numbers justify ($0.5000). For Cellectis SA the two are $0.5800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cellectis SA worth?
The market values Cellectis SA at about $109M (market capitalisation, as of Oct 28, 2026). Per share that is $1.08; our models calculate a fair value of $0.5000 per share.
What do the bullish and bearish scenarios say about CLLS?
Our models span a range for Cellectis SA: cautious scenario $0.3700, base $0.5000, optimistic $0.7500 per share (as of Oct 28, 2026, price $1.08). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cellectis SA (CLLS)?
Balance-sheet figures for Cellectis SA (as of Oct 28, 2026): return on equity −94.5%, debt of 0.68 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is CLLS from its 52-week high?
Cellectis SA trades at $1.08, about 80% below its 52-week high of $5.35 and 17% above the low of $0.9255 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5000 is for.
Which stocks are comparable to Cellectis SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cellectis SA stock attractive at the current price?
The data as of Oct 28, 2026: price $1.08, calculated fair value $0.5000 (−54%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLLS calculated?
We run Cellectis SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Cellectis SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cellectis SA (CLLS)?
The closing price on Oct 30, 2026 was $1.08. Our model-based fair value is $0.5000, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cellectis SA right now?
The price sits above even our optimistic bull case ($0.7500). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3700 to $0.7500) leaves room in how you read the outcome.

Key figures of Cellectis SA

How large is the market capitalisation of Cellectis SA (CLLS)?
The market capitalisation of Cellectis SA is $109M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cellectis SA (CLLS)?
The price-to-sales ratio of Cellectis SA is 1.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cellectis SA (CLLS)?
Earnings per share at Cellectis SA are $−0.6400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cellectis SA (CLLS)?
The net margin of Cellectis SA is −102% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cellectis SA (CLLS)?
The return on equity (ROE) of Cellectis SA is −94.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cellectis SA (CLLS)?
On an EBIT basis the return on assets of Cellectis SA is −22.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cellectis SA (CLLS)?
The operating margin of Cellectis SA is −341% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cellectis SA (CLLS)?
Revenue at Cellectis SA is growing −62.1% versus a year earlier (3y avg +56.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cellectis SA (CLLS) generate?
The free cash flow of Cellectis SA is −$42.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cellectis SA (CLLS) carry?
The net debt of Cellectis SA is $56.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cellectis SA in the live analysis

One click puts Cellectis SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.